Novartis is a top pharma company active in partnering, licensing and M&A in pharmaceuticals.
The path from scientific breakthrough to successful pharmaceutical brand depends on mobilizing the best global resources, expertise and experience.
At Novartis, the company often achieve success through close collaboration with partners who share a common vision and complementary strengths. A key Novartis priority is to build winning collaborations in the research of new medicines and vaccines.
Novartis has structured a streamlined collaboration process to provide rapid evaluation of potential opportunities, with the early involvement of senior management. Key elements of our collaboration process:
- A single gateway for all opportunities to facilitate initial contact and subsequent coordination of the evaluation process
- A single database supporting all aspects of the collaboration process
- Standard review criteria, comprising evaluation of the scientific basis of the opportunity, market potential and commercial viability
- Standard review and decision-making process driven by Business Development and Licensing (BD&L)
Summary of Novartis partnering interests
Novartis splits its partnering interests into distinct areas.
These can be summarized as follows:
- Oncology and hematology – committed to building winning collaborations to provide healthcare solutions that address unmet needs for patients. In the area of Oncology and Hematology, we are interested in innovative and novel targets in all indications
- Cardiovascular and metabolism – working to develop business in the following indications: diabetes, obesity, metabolic syndrome, atherosclerosis, novel treatments to improve lipid profile, innovative treatments for halting progression of congestive heart failure, antihypertensives with additional end organ benefits
- Immunology and infectious diseases – working to develop business in the following indications: hepatitis C and B and other viral diseases, hospital specialty antibiotics, rheumatoid arthritis, osteoarthritis (including pain), osteoporosis, muscle diseases, such as sarcopenia, immunomodulators for transplantation, treatment of end-stage and chronic renal disease, vascular access disease
- Respiratory – working to develop business in the following indications: asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis (IPF), primary pulmonary hypertension (PPH)
- Neuroscience and ophthalmics – working to develop business in the following indications: neurodegeneration, multiple sclerosis, mood and anxiety disorders, psychotic disorders, "wet" age-related macular degeneration, "dry" age-related macular degeneration, glaucoma
- Molecular diagnostics – working to develop molecular diagnostics across therapeutic areas.
For the latest detail on Novartis’s partnering interests, visit the partnering section of Novartis website > go to About Novartis > Collaborations for details.
Novartis are routinely present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a small amount of time.
Events with Novartis presence include but are not limited to:
- BIO International Convention and Business Forum
- BioPartnering Future Europe / BioPartnering North America
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Novartis in person visit Current Partnering’s Event calendar.
In addition, you can find a full list of events where Novartis will be present for partnering discussions, visit the partnering section of Novartis website > go to About Novartis > Collaborations for details.
Contacting Novartis for partnering
Novartis can be contacting in relation to partnering through a number of channels.
Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
Direct contact: there are several sources of direct contact with Novartis business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Novartis do not publish a list of contacts on their website, so unless you cannot find a direct contact elsewhere use the contact form here.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel. Many of Novartis business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Novartis LinkedIn page here
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. Novartis provides an online opportunity submission form which can be found by partnering section of Novartis website > go to About Novartis > Collaborations for details.
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Novartis
Report: Partnering Deals and Alliances with Big Pharma
Available resources for deal coverage for Novartis
Read: more on Novartis company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk